CohBar
CohBar is a biotechnology company focused on developing innovative therapeutics targeting the mitochondria to address age-related diseases and metabolic dysfunction. Leveraging its proprietary platform, CohBar identifies and advances novel peptides derived from mitochondrial DNA with the potential to treat a range of chronic conditions, including non-alcoholic steatohepatitis (NASH), obesity, and fibrotic diseases. The company’s research aims to harness the critical role of mitochondria in cellular health to develop first-in-class treatments. CohBar’s commitment to scientific excellence and translational research positions it at the forefront of mitochondrial medicine, with a robust pipeline of preclinical and clinical-stage candidates designed to improve patient outcomes and address significant unmet medical needs.
